Davion Healthcare Plc, a leading medical device manufacturer, has announced the granting of a Global Manufacturing and Distribution Licence for its non-invasive BreastCheck™ home test for Breast Anomalies including Breast Cancer, to Rhode Island (USA) based NeuRX Health Inc.
For this licence, NeuRX will pay Davion the sum of $120 Million USD, together with ongoing royalty payments on global sales of BreastCheck™. The two parties have signed binding headline terms with the completion of the full licence to be filed early January 2024.
The home test takes just fifteen minutes with the results being immediate and is registered as a Class1 Medical Device with regulatory authorities in the USA (FDA), Europe (CE) and the United Kingdom (UKCA). BreastCheck™ will be available from Pharmacies, larger Retail Outlets and Online towards the end of the first quarter 2024.
Jack Kaye, Davion’s CEO, said: “We are thrilled to appoint NeuRX Health Inc as our global manufacturer and distributor for this important product. The team at NeuRX have extensive experience and expertise in both manufacturing and distribution internationally of medical products.”
Robert Hainey, NeuRX Health Inc CEO, added: “We are enthusiastic about the prospects this global licencing agreement gives us. Davion’s BreastCheck™ product is a global first, for which we expect there will be great demand internationally.”
This licencing agreement follows on from Davion’s recent announcement of a $30 million IPO fundraising round alongside a NADAQ listing of the company’s ADRs through The Bank of New York Melon and further supports this process. Davion looks forward to a successful IPO and subsequent listing on the NASDAQ stock exchange, which it anticipates will (subject to market forces) take place in the first quarter of 2024.
Munro Forbes, Media Relations Manager at Davion Healthcare Plc, said: “We remain committed to delivering exceptional value to our shareholders whilst driving innovation within the medical sector.”
Davion Healthcare Plc is a leading medical device manufacturer focused on transforming the ordinary into the extraordinary. Their mission is to create and manage an environment for the secure development of new medical devices, with a current focus on accessible products available for self-use in the comfort of a person’s own home utilising smart technology interfaces. They are committed to empowering individuals to take control of their health and well-being by providing them with the tools they need to detect potential health issues at an early stage.
Davion Healthcare Plc has granted a Global Manufacturing and Distribution Licence for its non-invasive BreastCheck™ home test for Breast Anomalies including Breast Cancer, to Rhode Island (USA) based NeuRX Health Inc. The agreement sees NeuRX paying Davion the sum of $120 Million USD for the licence, together with ongoing royalty payments on global sales of BreastCheck™. The home test takes just fifteen minutes, and the results are immediate. It is registered as a Class1 Medical Device with regulatory authorities in the USA (FDA), Europe (CE) and the United Kingdom (UKCA). BreastCheck™ will be available towards the end of the first quarter 2024 internationally, from Pharmacies, larger Retail Outlets and Online.
Jack Kaye, CEO of Davion Healthcare Plc, said: “We are thrilled to appoint NeuRX Health Inc as our global manufacturer and distributor for this important product. The team at NeuRX have extensive experience and expertise in both manufacturing and distribution internationally of medical products.”
Robert Hainey, NeuRX Health Inc CEO, added: “We are enthusiastic about the prospects this global licencing agreement gives us. Davion’s BreastCheck™ product is a global first, for which we expect there will be great demand internationally.”
The licencing agreement follows on from Davion’s recent announcement of a $30 million IPO fundraising round alongside a NADAQ listing of the company’s ADRs through The Bank of New York Melon. Davion looks forward to a successful IPO and subsequent listing on the NASDAQ stock exchange, which it anticipates will (subject to market forces) take place in the first quarter of 2024.
Munro Forbes, Media Relations Manager at Davion Healthcare Plc, said: “We remain committed to delivering exceptional value to our shareholders whilst driving innovation within the medical sector.”
Davion Healthcare Plc, a leading medical device manufacturer, has announced the granting of a Global Manufacturing and Distribution Licence for its non-invasive BreastCheck™ home test for Breast Anomalies including Breast Cancer, to Rhode Island (USA) based NeuRX Health Inc. The licence comes with
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.